Telephus Medical LLC Announces CEO Mark Benedyk, PhD to Serve on Panel “Advances Against Rare and Resistant Pathogens” at Anti-Infectives Rx Invitation-Only Conference

September 18, 2017, San Diego – Telephus Medical LLC (Telephus), a biotechnology company focused on development of novel antibody therapies for antibiotic-resistant staphylococcal infections, today announced that CEO and President Mark Benedyk, PhD will be attending Anti-Infectives Rx, an invitation-only conference where he will be participating on an industry panel titled “Advances Against Rare and Resistant Pathogens.”

Anti-Infectives Rx is a conference for industry CEOs, life science leaders, key academics and investors focused on issues facing the development of anti-infective, antiviral, and antibacterial therapies. Conference participants will discuss regulatory issues, sustainability, partnering, as well as microbiome and immunotherapy as the new wave of anti-infectives. The conference is being held in Boston on September 19.

Dr. Benedyk stated, “I am delighted to serve on this panel which is focused on rare and antibiotic-resistant pathogens. Our focus at Telephus is on antibiotic-resistant bone infections due to MRSA, specifically MRSA osteomyelitis, a devastating bone infection that affects approximately 70,000 individuals in the US annually and arises from complications of hip or knee replacement or because of open fractures. As antibiotic resistance becomes increasingly prevalent across the globe, the need for new approaches becomes more urgent. Our TPH 101 immunotherapy to treat these infections is designed to provide significant patient benefits compared to the extensive surgery and prolonged high-dose regimens of antibiotics, which is currently standard of care for MRSA bone infections, an approach with a 40% failure rate and significant risk of death or amputation.”

About Telephus Medical
Telephus Medical is developing a pipeline of monoclonal antibody products designed to fight methicillin-resistant S. aureus (MRSA) bone infection and accompanying tissue destruction – MRSA osteomyelitis. The focus of our lead program, TPH 101, is the treatment of antibiotic-resistant periprosthetic joint infections, devastating bone infections in patients who have received hip or knee replacements. Staphylococcal bacteria are the majority of pathogens found in these patients, and MRSA are the most persistent and devastating bacteria in these infections, which often result in amputation or death. Telephus is dedicated to improving the lives of patients by developing new therapeutics that harness the power of patients’ own immune systems to fight infection. Telephus is a private biotech company located in San Diego, California.

Additional information about Telephus can be found at www.telephusmedical.com.

Media Contact:
Jessica Yingling, Ph.D.
Little Dog Communications Inc.
+1.858.344.8091
jessica@litldog.com

Source: Telephus Medical LLC